Anixa Biosciences, Inc.
ANIX · NASDAQ
10/31/2024 | 10/31/2023 | 10/31/2022 | 10/31/2021 | |
|---|---|---|---|---|
| Market Cap | $112 | $98 | $170 | $145 |
| - Cash | $1 | $1 | $12 | $29 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $111 | $97 | $158 | $117 |
| Revenue | $0 | $0 | $2,469 | $1 |
| % Growth | -100% | -100% | 481,656.1% | – |
| Gross Profit | -$0 | $0 | $2,469 | $0 |
| % Margin | – | 23.3% | 100% | 24.9% |
| EBITDA | -$13 | -$11 | -$14 | -$13 |
| % Margin | – | -5,221.4% | -0.6% | -2,552.4% |
| Net Income | -$13 | -$10 | -$13 | -$13 |
| % Margin | – | -4,671.9% | -0.5% | -2,526.2% |
| EPS Diluted | -0.39 | -0.32 | -0.44 | -0.45 |
| % Growth | -21.9% | 27.3% | 2.2% | – |
| Operating Cash Flow | -$7 | -$6 | -$6 | -$5 |
| Capital Expenditures | $0 | $0 | $0 | $0 |
| Free Cash Flow | -$7 | -$6 | -$6 | -$5 |